摘要
目的：分析贝伐珠单抗治疗多种恶性肿瘤的不良反应的临床表现及发生率。方法：采用回顾性分析法,对我院2012年1月-2012年12月使用贝伐珠单抗治疗的60例病例进行分析。其中贝伐珠单抗的给药剂量4~7.5 mg·kg-1,给药途径56例为静脉滴注,3例为肝动脉泵入,1例为腹腔灌注。结果：60例可评价患者共用药252次,发生贝伐珠单抗说明书报道的不良反应167次,涉及53例患者,其中高度怀疑与贝伐珠单抗相关的不良反应65次,涉及31例患者。未发生致死性不良反应。出血发生率31.67%,高血压发生率16.67%,蛋白尿发生率3.33%,静脉血栓栓塞发生率1.67%。未发生胃肠道穿孔、瘘,呼吸系统紊乱,充血性心力衰竭,可逆性后脑白质病综合征等不良反应。结论：贝伐珠单抗严重不良事件发生率较低,与化疗药和其他靶向治疗药物联合应用安全性较好。临床在应用贝伐珠单抗过程中,对于不良反应应做到定期监测及时处理。
Objective： To evaluate adverse reactions of bevacizumab in the treatment of cancer.Methods： Totally 60 patients in our hospital using the bevacizumab during Jan.2012 to Dec.2012 were retrospectively analyzed.Bevacizumab dose per patient was 4 ~ 7.5 mg·kg-1.The routes of administration were intravenous infusion in 56 patients,hepatic artery infusion in 3 patients,and peritoneal perfusion in 1 patient.Results： Sixty patients were evaluable,including 252 medications.A total of 167 adverse reactions occurred in 53 patients,including 65 highly suspected adverse reactions related to bevacizumab in 31 patients.No fatal adverse reactions were reported.The incidences of hemorrhage,hypertension,proteinuria and venous thromboembolism were 31.67%,16.67%,3.33% and 1.67%.However,there was no gastrointestinal perforation,fistula,respiratory system disorders,congestive heart failure,and reversible posterior cerebral white matter disease syndrome.Conclusion： The incidence of serious adverse events of bevacizumab is low,and it is safe to be combined with chemotherapy and other targeted therapies.The adverse reactions of bevacizumab should be regularly monitored and timely treated.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2013年第17期2097-2102,共6页
Chinese Journal of New Drugs
